MyoGene Bio is Committed to Developing Cutting Edge Therapies for Muscle Diseases
Our lead program, MyoDys45-55, is an effective gene editing treatment for the devastating, fatal disease, Duchenne muscular dystrophy
Embedded Files
Duchenne muscular dystrophy has no cure but ongoing research and clinical trials finally offer hope for this devastating muscle wasting disease. MyoDys45-55 is designed to permanently fix the underlying cause of the disease for half of all Duchenne patients using this single platform. Future programs will develop similar strategies for more patients and other muscle diseases. MyoGene Bio’s goal is to have a significant impact on disease progression for devastating muscle disorders.
MyoGene Bio is Granted Orphan Drug and Rare Pediatric Disease Designations
November 19, 2024
MyoGene is pleased to announce that FDA has granted Orphan Drug Designation and Rare Pediatric Disease Designation to MyoDys45-55 for Duchenne muscular dystrophy.
MyoGene Bio is Awarded 4th Place in the Entrepreneurship World Cup
November 11, 2024
MyoGene Bio is excited to have been awarded 4th Place in the Early Stage competition at the Entrepreneurship World Cup in Riyadh, Saudi Arabia!
MyoGene Bio is Awarded an NIH Grant to Further Preclinical Development
September 1, 2024
MyoGene is pleased to report additional grant funding from the National Center for Advancing Translational Sciences at the National Institutes of Health to conduct additional preclinical studies.
Page updated
Report abuse